ArticleEuropean journal of medical research2025
Potential of APOBEC3B as a therapeutic target and its role in bladder cancer onset and progression.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis investigation aims to investigate the impact of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3B (APOBEC3B/A3B) on the malignant biological characteristics of bladder cancer. Additionally, the study examines the potential mechanisms of APOBEC3B's action to assess its feasibility as a therapeutic strategy for bladder cancer.
methodsThe investigation first confirmed APOBEC3B expression in bladder cancer using bioinformatics and experimental validation. Then, the relationship between APOBEC3B expression and various parameters was analyzed, with gene set enrichment analysis (GSEA) to explore pathways. The IMvigor210 cohort was analyzed to validate the correlation between APOBEC3B expression and immunotherapy efficacy.
resultsCellular and animal experiments further validated the impact of APOBEC3B on bladder cancer biology. High APOBEC3B expression in bladder cancer patients is associated with an increased frequency of somatic mutations. APOBEC3B expression levels are significantly correlated with the infiltration of various immune cells and the expression of immune checkpoint-related genes. Moreover, high APOBEC3B expression is associated with increased tumor mutation burden. In the IMvigor210 cohort, APOBEC3B expression is significantly upregulated in individuals with positive responses to immunotherapy. Our study suggests that APOBEC3B plays a key role in promoting the initiation and progression of bladder cancer. Additionally, bladder cancer cells with overexpressed APOBEC3B can enhance the polarization of M2-like tumor-associated macrophages.
conclusionThe research demonstrates that APOBEC3B exhibits high expression levels in bladder cancer and can enhance its malignant biological behavior. APOBEC3B may serve as a promising therapeutic target in future treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.